Payment overview · 2025
General Payments
$564.95
6 reported records · 3 companies
Healthcare provider profile · identity verified
Albert M Edwards, M.D
Allopathic & Osteopathic Physicians|Family Medicine · POWDER SPRINGS, GA · NPI 1265505531
Verified facts
What the public records show
CMS Open Payments records show Albert M Edwards, M.D received $564.95 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 63.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $360.25 | 63.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $120.65 | 21.4% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $84.05 | 14.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $564.95 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $232.78 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $127.47 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $120.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 347 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 324 | 33 |
| Alprazolam | Alprazolam | 305 | 36 |
| Estradiol | Estradiol | 283 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 50 |
| Gabapentin | Gabapentin | 192 | 44 |
| Lisinopril | Lisinopril | 181 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 165 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 165 | 25 |
| Fenofibrate | Fenofibrate | 163 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 30 |
| Tramadol Hcl | Tramadol Hcl | 126 | 23 |
| Atorvastatin Calcium | Atorvastatin Calcium | 111 | 31 |
| Ozempic | Semaglutide | 108 | 22 |
| Promethazine Hcl | Promethazine Hcl | 108 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 24 |
| Metformin Hcl | Metformin Hcl | 104 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 33 |
| Farxiga | Dapagliflozin Propanediol | 99 | 23 |
| Carisoprodol | Carisoprodol | 98 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 97 | 27 |
| Pregabalin | Pregabalin | 93 | 15 |
| Carvedilol | Carvedilol | 90 | 25 |
| Ezetimibe | Ezetimibe | 89 | 18 |
| Potassium Chloride | Potassium Chloride | 87 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 18 |
| Montelukast Sodium | Montelukast Sodium | 83 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 83 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 19 |
| Ibuprofen | Ibuprofen | 80 | 18 |
| Meloxicam | Meloxicam | 80 | 27 |
| Trulicity | Dulaglutide | 76 | 13 |
| Losartan Potassium | Losartan Potassium | 75 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 14 |
| Ondansetron Odt | Ondansetron | 72 | 22 |
| Simvastatin | Simvastatin | 70 | 20 |
| Bupropion Xl | Bupropion Hcl | 68 | 18 |
| Methadone Hcl | Methadone Hcl | 65 | suppressed |
| Omeprazole | Omeprazole | 63 | 20 |
| Aripiprazole | Aripiprazole | 62 | suppressed |
| Celecoxib | Celecoxib | 61 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 14 |
| Furosemide | Furosemide | 57 | 19 |
| Temazepam | Temazepam | 56 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 54 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 49 | suppressed |
| Acyclovir | Acyclovir | 46 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 12 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 38 | suppressed |
| Progesterone | Progesterone, Micronized | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 14 |
| Prednisone | Prednisone | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Famotidine | Famotidine | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 11 |
| Methylprednisolone | Methylprednisolone | 31 | 26 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 24 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Emgality Pen | Galcanezumab-Gnlm | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 14 |
| Linzess | Linaclotide | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Gralise | Gabapentin | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $564.95 · 6 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error